F
Firzan Nainu
Researcher at Hasanuddin University
Publications - 114
Citations - 2352
Firzan Nainu is an academic researcher from Hasanuddin University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 14, co-authored 60 publications receiving 580 citations. Previous affiliations of Firzan Nainu include James Cook University & University of Queensland.
Papers
More filters
Journal ArticleDOI
Impact of heavy metals on the environment and human health: Novel therapeutic insights to counter the toxicity
Saikat Mitra,Arka Chakraborty,Abu Montakim Tareq,Talha Bin Emran,Firzan Nainu,Ameer Khusro,A.M. Idris,Mayeen Uddin Khandaker,Hamid Osman,Fahad A. Alhumaydhi,Jesus Simal-Gandara +10 more
TL;DR: In this article , a review aimed to explore the environmental consequences of the heavy metals, toxicity to the human health, as well as novel therapeutics development from the natural resources, and highlight the nanotechnological and nanomedicinal applications to treat heavy metal toxicity.
Journal ArticleDOI
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Rekha Khandia,Shailja Singhal,Taha Alqahtani,Mohammad Amjad Kamal,Nahed A. El-Shall,Firzan Nainu,P. A. Desingu,Kuldeep Dhama +7 more
TL;DR: The most recently emerged variant of concern (VOC) is the Omicron (B.1.529) that has evolved due to the accumulation of high numbers of mutations especially in the spike protein, raising concerns for its ability to evade from pre-existing immunity acquired through vaccination or natural infection as well as overpowering antibodies-based therapies as mentioned in this paper .
Journal ArticleDOI
Remdesivir and its antiviral activity against COVID-19: A systematic review.
Andri Frediansyah,Andri Frediansyah,Firzan Nainu,Kuldeep Dhama,Mudatsir Mudatsir,Harapan Harapan +5 more
TL;DR: Although remdesivir has been used as a compassionate drug for treating COVID-19 patients, it has only moderate efficacy and more efficacy assessments are urgently warranted in clinical trials.
Journal ArticleDOI
Predictors of COVID-19 severity: a systematic review and meta-analysis
Mudatsir Mudatsir,Jonny Karunia Fajar,Jonny Karunia Fajar,Laksmi Wulandari,Gatot Soegiarto,Muhammad Ilmawan,Yeni Purnamasari,Bagus Aulia Mahdi,Galih Dwi Jayanto,Suhendra Suhendra,Yennie Ayu Setianingsih,Romi Hamdani,Daniel Alexander Suseno,Kartika Agustina,Hamdan Yuwafi Naim,Muchamad Muchlas,Hamid Hunaif Dhofi Alluza,Nikma Alfi Rosida,Mayasari Mayasari,Mustofa Mustofa,Adam Hartono,Richi Aditya,Firman Prastiwi,Fransiskus Xaverius Meku,Monika Sitio,Abdullah Azmy,Anita Surya Santoso,Radhitio Adi Nugroho,Camoya Gersom,Ali A. Rabaan,Sri Masyeni,Firzan Nainu,Abram L. Wagner,Kuldeep Dhama,Harapan Harapan +34 more
TL;DR: More than 30 risk factors are associated with a higher risk of severe COVID-19, and these may serve as useful baseline parameters in the development of prediction tools for CO VID-19 prognosis.
Journal ArticleDOI
Covid-19 and dengue: Double punches for dengue-endemic countries in Asia.
Harapan Harapan,Mirza Ryan,Benediktus Yohan,Rufika Shari Abidin,Firzan Nainu,Ahmed Rakib,Israt Jahan,Talha Bin Emran,Irfan Ullah,Kritu Panta,Kuldeep Dhama,R. Tedjo Sasmono +11 more
TL;DR: The issue of Covid‐19 and dengue fever misdiagnosis is raised, not only in a clinical setting but also with regards to cross‐reactivity between SARS‐CoV‐2 and DENV antibodies.